Drug
Arumakimig clinical trials
Also written MAS825.
- studies test it
- 8
- open now
- 2
- in phase 3
- 1
- first study started
- 2019
Keep track of what changes. Save the arumakimig studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
8 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2020 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 1
Novartis Pharmaceuticals (7) · The Hospital for Sick Children (1)
Often tested with
Tested in the same studies.
Iscalimab (1) · LYS-006 (1) · Remibrutinib (1) · Ianalumab (1) · NLRP3 Inhibitor DFV890 (1)
Studies
Open first, then newest update. How each study uses arumakimig is read from its arms, and is right about nine times in ten.
Testing it · 8
- A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) PeriodRecruitingPhase 2Novartis PharmaceuticalsNCT07748624Written as Arumakimig
- A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseaseRecruitingPhase 2Novartis PharmaceuticalsNCT07203001Written as MAS825
- Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis SuppurativaCompletedPhase 2Novartis PharmaceuticalsNCT03827798Written as MAS825
- Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 MutationsActive, not recruitingPhase 2Novartis PharmaceuticalsNCT04641442Written as MAS825
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)CompletedPhase 2Novartis PharmaceuticalsNCT06097663Written as MAS825
- A Single-patient Clinical Trial of MAS825 in a Patient With XIAP DeficiencyCompletedPhase 3The Hospital for Sick ChildrenNCT06309823Written as MAS825
- A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy VolunteersCompletedPhase 1Novartis PharmaceuticalsNCT04665154Written as MAS825
- Study of Efficacy and Safety of MAS825 in Patients With COVID-19CompletedPhase 2Novartis PharmaceuticalsNCT04382651Written as MAS825
Codes
What other systems call arumakimig · ClinicalTrials.gg INT016604
- UNII (FDA) FWE2G0Y2W3ARUMAKIMIGOne source FDA
- NCI Thesaurus C215726ArumakimigOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FWE2G0Y2W3 | ARUMAKIMIG | One source FDA |
| NCI Thesaurus | C215726 | Arumakimig | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.